knowledge -WSS

knowledge

author：focus 2025-09-30 16:26:44 - browse：9517

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： 2023 STAT Wunderkinds: get to know the winners

WSS

Pharma companies must ensure equitable access to obesity drugs

Pharmacists can make shortage drugs, but at what cost?

The EU Joint Clinical Assessment needs to live up to its promise

Senate committee scrutinizes Medicare Advantage brokers

My daughter's legacy lives on through her writing, phage therapy

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Wikipedia

knowledge

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Moderna says combo Covid

Walensky prepares to leave CDC — and Congress — behind

California wildfire smoke linked to 52,000 early deaths, study says

Peter Hotez and the public health issue of online harassment

5 takeaways from STAT's examination of Zynex Medical

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Medical device trials still don't enroll enough women, study finds

How one medical school became remarkably diverse

2023 STAT Wunderkinds: get to know the winners

hotspot

CEOs share strategies for surviving biotech slump

FDA struggles to regulate food additives, sometimes for decades

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Medical device trials still don't enroll enough women, study finds

Beam Therapeutics to lay off 20% of its staff, re

STAT Readout Newsletter: Today's biggest biotech updates

Wikipedia

entertainment

focus

knowledge